Exagen's Q1 2026 slide deck is now public. Investors will parse AVISE test volumes, average revenue per test, and cash runway for signals on the path to breakeven.
Exagen Inc. (NASDAQ: XGN) published its first-quarter 2026 earnings call presentation on May 12, making the slide deck available to investors ahead of the accompanying conference call. The release itself contained no summary financial tables or guidance figures, leaving the market to parse the deck directly for revenue trends, test volume growth, and cash consumption metrics.
For a small-cap diagnostics company where quarterly swings in reimbursement and testing volumes can move the stock by double digits, the presentation deck is often the first hard data point after the quiet period. The absence of a simultaneous press release with headline numbers means the initial market reaction will be shaped by how quickly investors can extract the key operating metrics from the slides.
Exagen's core product is the AVISE line of diagnostic tests, which help rheumatologists differentiate autoimmune diseases like lupus and rheumatoid arthritis. The company generates revenue from test fees, with a mix of commercial payor reimbursement and patient self-pay. Consequently, two numbers dominate every quarterly update: test volume and average revenue per test.
Test volume signals adoption among rheumatologists and the success of the company's sales force expansion. Average revenue per test reflects the payor mix, prior authorization success, and collection rates. When both metrics move in the same direction, the revenue line can inflect quickly. When they diverge, the stock often reprices as the market reassesses the path to cash-flow breakeven.
Without a headline release, the slide deck becomes the primary source for the quarter's financials. Investors will scan for several specific items:
Exagen's management typically uses the presentation to highlight operational milestones, such as new payor contracts, publications supporting AVISE's clinical utility, or progress toward the next-generation AVISE CTD platform. Any mention of Medicare reimbursement rates or commercial payor coverage decisions will be scrutinized, as these directly affect the ASP trajectory.
The slide deck publication is the first step. The earnings call itself, typically held the same day or the following morning, will provide management's commentary on the numbers and any forward-looking statements. For Exagen, the call often clarifies whether revenue growth is accelerating toward the company's long-term target of sustainable profitability, or whether cash burn remains elevated.
Traders and investors will also watch for the formal 10-Q filing, which contains granular detail on revenue recognition, accounts receivable aging, and any changes in the fair value of warrant liabilities. That filing often lands a few days after the call and can surface balance-sheet items not visible in the slide deck.
The immediate catalyst path is straightforward: the market will digest the deck, react to the call, and then adjust positions ahead of the 10-Q. For a stock with an average daily volume that can be thin, the sequence of information releases can create sharp intraday swings. The next concrete decision point is whether the Q1 numbers support the full-year revenue guidance that management is expected to reiterate or update on the call.
For broader context on how small-cap healthcare names trade around earnings, see our market analysis section. The diagnostics sector remains sensitive to utilization trends and payor policy shifts, making each quarterly update a potential re-rating event.
Drafted by the AlphaScala research model and grounded in primary market data – live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.